Date: 2018-10-04
Type of information: Licensing agreement
Compound: shRNA technology
Company: Horizon Discovery (UK) Celyad (Belgium)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: shRNA
Disease:
Details:
- • On October 4, 2018, Celyad announced an exclusive agreement with Horizon Discovery Group for the use of its shRNA technology to generate Celyad’s second non-gene-edited allogeneic platform.
- Celyad recently announced its first-in-class non-gene edited allogeneic CAR-T candidate, CYAD-101 a non-gene-edited allogeneic NKG2D-based CAR using the TIM (TCR Inhibiting Molecule). As a result of the agreement with Horizon Discovery, Celyad now also has access to a novel shRNA-based platform.
- Data from preclinical studies demonstrating the versatility of the shRNA platform in the allogeneic setting, will be presented at the upcoming 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C., November 7th – 11th. These promising preclinical data will pave the way for the next steps in the development of Celyad’s differentiated non-gene edited allogeneic approach to CAR-T cell therapy.
Financial terms:
Latest news:
Is general: Yes
